Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18890086 | 0.83 | LMNA (0.41) | LMNAPARP1TSHRNPSR1IDO1 | |
| SCHEMBL27901063 | 0.80 | APP (0.41) | APPAAK1LMNAPARP1TSHR | |
| SCHEMBL25279555 | 0.80 | S1PR3 (0.45) | APPAAK1IDO1S1PR3 | |
| SCHEMBL27395438 | 0.80 | APP (0.41) | APPAAK1LMNAKMT2AALDH1A1 | |
| SCHEMBL26508769 | 0.76 | IDO1 (0.40) | APPLMNAPARP1TSHRIDO1 | |
| SCHEMBL11378154 | 0.75 | ACHE (0.46) | LMNATSHRNPSR1KDM4EKMT2A | |
| SCHEMBL17634288 | 0.74 | GSK3B (0.45) | APP | |
| SCHEMBL20166011 | 0.73 | LMNA (0.36) | APPLMNATSHRKDM4EKMT2A | |
| SCHEMBL355454 | 0.73 | CES2 (0.53) | AAK1LMNATSHRNPSR1KMT2A | |
| SCHEMBL3745868 | 0.72 | SLC7A5 (0.44) | APPAAK1LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4448500-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114822-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | APP 4755/4885AAK1 837/4885LMNA 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.